



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Methyl brevifolincarboxylate

Cat. No.:	HY-N7647
CAS No.:	154702-76-8
Molecular Formula:	C ₁₄ H ₁₀ O ₈
Molecular Weight:	306.22
Target:	Influenza Virus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor. Methyl brevifolincarboxylate has anti-oxidant activity. Methyl brevifolincarboxylate also inhibits platelet aggregation, lipid metabolism and inflammation^{[1][2][4][5][6]}.

In Vitro Methyl brevifolincarboxylate exhibits significant DPPH radical scavenging activity with an IC₅₀ value of 8.9 μM^[2]. Methyl brevifolincarboxylate (10 and 30 μM) inhibits NO and TNF-α production in LPS stimulated macrophages^[2]. Methyl brevifolincarboxylate (1 and 10 μM) inhibits Norepinephrine (HY-13715)-induced contractions of rat aorta^[3]. Methyl brevifolincarboxylate (5 μM) inhibits platelet aggregation by 73.5%^[4]. Methyl brevifolincarboxylate exhibits inhibitory activity against influenza virus A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) with IC₅₀s of 27.16 μM and 33.41 μM^[5]. Methyl brevifolincarboxylate (10-80 μM, 48 h) reduces TG Levels in OA-Treated SK-HEP-1 Cells and Primary Murine Hepatocytes^[6]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[6]

Cell Line:	SK-HEP-1 cells
Concentration:	10, 20, 40, 80 μM
Incubation Time:	48 h
Result:	Reduced the protein levels of FASN, SREBP-1c and ACC1. Increased the expression of PPAR-α.

REFERENCES

- [1]. Iizuka T, et al. Vasorelaxant effects of methyl brevifolincarboxylate from the leaves of Phyllanthus niruri. *Biol Pharm Bull.* 2006 Jan;29(1):177-9.
- [2]. Iizuka T, et al. Inhibitory effects of methyl brevifolincarboxylate isolated from Phyllanthus niruri L. on platelet aggregation. *Biol Pharm Bull.* 2007 Feb;30(2):382-4.
- [3]. Wu QY, et al. Chromatographic fingerprint and the simultaneous determination of five bioactive components of geranium carolinianum L. water extract by high performance liquid chromatography. *Int J Mol Sci.* 2011;12(12):8740-8749.

[4]. Fang SH, et al. Anti-oxidant and inflammatory mediator's growth inhibitory effects of compounds isolated from Phyllanthus urinaria. J Ethnopharmacol. 2008;116(2):333-340.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA